

Kathryn Tinckam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5572548/publications.pdf>

Version: 2024-02-01

84
papers

4,115
citations

101543

36
h-index

118850

62
g-index

85
all docs

85
docs citations

85
times ranked

4603
citing authors

#	ARTICLE	IF	CITATIONS
1	KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. <i>Transplantation</i> , 2020, 104, S11-S103.	1.0	306
2	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. <i>American Journal of Transplantation</i> , 2018, 18, 1604-1614.	4.7	205
3	Human T and Natural Killer Cells Possess a Functional Renin-Angiotensin System. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1093-1102.	6.1	194
4	The Role of Donor-Specific HLA Alloantibodies in Liver Transplantation. <i>American Journal of Transplantation</i> , 2014, 14, 779-787.	4.7	182
5	Delayed Graft Function and the Risk for Death with a Functioning Graft. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 153-161.	6.1	177
6	Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3114-3122.	6.1	172
7	Utility of HLA Antibody Testing in Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1489-1502.	6.1	155
8	De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 596-606.	5.6	138
9	Survival in Sensitized Lung Transplant Recipients With Perioperative Desensitization. <i>American Journal of Transplantation</i> , 2015, 15, 417-426.	4.7	134
10	Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. <i>Kidney International</i> , 2005, 68, 1866-1874.	5.2	128
11	The profile of cardiac patients with renal artery stenosis. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1606-1613.	2.8	127
12	Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. See Editorial by Colvin, p. 1953.. <i>Kidney International</i> , 2003, 63, 1888-1893.	5.2	122
13	HLA-DR and -DQ Eplet Mismatches and Transplant Glomerulopathy: A Nested Case-Control Study. <i>American Journal of Transplantation</i> , 2015, 15, 137-148.	4.7	116
14	Kidney paired donation: principles, protocols and programs. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1276-1285.	0.7	101
15	Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 649-657.	8.1	76
16	Should HLA Mismatch Acceptability for Sensitized Transplant Candidates Be Determined at the High-Resolution Rather Than the Antigen Level?. <i>American Journal of Transplantation</i> , 2015, 15, 923-930.	4.7	73
17	A Survey of Current Practice for Antibody-Mediated Rejection in Heart Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 1069-1074.	4.7	67
18	Safety and Efficacy of a Calcineurin Inhibitor Avoidance Regimen in Pediatric Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1735-1745.	6.1	62

#	ARTICLE	IF	CITATIONS
19	Mechanisms and Role of HLA and non-HLA Alloantibodies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 404-414.	4.5	62
20	Antibody Mediated Rejection Associated With Complement Factor H-Related Protein 3/1 Deficiency Successfully Treated With Eculizumab. <i>American Journal of Transplantation</i> , 2012, 12, 2546-2553.	4.7	61
21	Survival Analysis in the Presence of Competing Risks: The Example of Waitlisted Kidney Transplant Candidates. <i>American Journal of Transplantation</i> , 2016, 16, 1958-1966.	4.7	61
22	Identification of risk epitope mismatches associated with de novo donor-specific HLA antibody development in cardiothoracic transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 2924-2933.	4.7	61
23	The Relative Importance of Cytokine Gene Polymorphisms in the Development of Early and Late Acute Rejection and Six-Month Renal Allograft Pathology. <i>Transplantation</i> , 2005, 79, 836-841.	1.0	58
24	Epitopes as characterized by antibody-verified eplet mismatches determine risk of kidney transplant loss. <i>Kidney International</i> , 2020, 97, 778-785.	5.2	58
25	Renal Transplantation in Patients With Positive Lymphocytotoxicity Crossmatches: One Center's Experience. <i>Transplantation</i> , 2008, 86, 96-103.	1.0	57
26	Immune Sensitization and Mortality in Wait-Listed Kidney Transplant Candidates. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 570-578.	6.1	57
27	Focal peritubular capillary C4d deposition in acute rejection. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1382-1388.	0.7	49
28	A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection. <i>Kidney International</i> , 2015, 87, 182-194.	5.2	46
29	Absence of Donor-Specific Anti-HLA Antibodies After ABO-Incompatible Heart Transplantation in Infancy: Altered Immunity or Age?. <i>American Journal of Transplantation</i> , 2010, 10, 149-156.	4.7	43
30	Differential cytokine genotype frequencies among Canadian Aboriginal and Caucasian populations. <i>Genes and Immunity</i> , 2005, 6, 140-144.	4.1	42
31	Histocompatibility methods. <i>Transplantation Reviews</i> , 2009, 23, 80-93.	2.9	42
32	Factors associated with anti-human leukocyte antigen antibodies in patients supported with continuous-flow devices and effect on probability of transplant and post-transplant outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 685-692.	0.6	42
33	Screening for De Novo Anti-Human Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients Does Not Predict Acute Rejection. <i>Transplantation</i> , 2010, 89, 178-184.	1.0	40
34	Clinical Utility of Complement Dependent Assays in Kidney Transplantation. <i>Transplantation</i> , 2018, 102, S14-S22.	1.0	39
35	Delayed Graft Function and the Risk of Death With Graft Function in Living Donor Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2010, 56, 961-970.	1.9	38
36	Detecting donor-specific antibodies: the importance of sorting the wheat from the chaff. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 37-52.	1.5	38

#	ARTICLE	IF	CITATIONS
37	Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1825-1833.	0.7	36
38	Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2012, 14, 575-583.	1.7	35
39	Kidney Paired Donation Protocol for Participating Donors 2014. <i>Transplantation</i> , 2015, 99, S1-S88.	1.0	35
40	Passenger Lymphocyte Syndrome With or Without Immune Hemolytic Anemia in all Rh-Positive Recipients of Lungs From Rhesus Alloimmunized Donors: Three New Cases and a Review of the Literature. <i>Transfusion Medicine Reviews</i> , 2009, 23, 134-145.	2.0	34
41	cPRA Increases With DQA, DPA, and DPB Unacceptable Antigens in the Canadian cPRA Calculator. <i>American Journal of Transplantation</i> , 2015, 15, 3194-3201.	4.7	34
42	Antibody-Mediated Rejection: An Evolving Entity in Heart Transplantation. <i>Journal of Transplantation</i> , 2012, 2012, 1-10.	0.5	32
43	Re-Examining Risk of Repeated HLA Mismatch in Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2833-2841.	6.1	32
44	Ex vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs. <i>Science Translational Medicine</i> , 2022, 14, eabm7190.	12.4	30
45	Donor specific HLA antibodies & allograft injury: mechanisms, methods of detection, manifestations and management. <i>Transplant International</i> , 2018, 31, 1059-1070.	1.6	25
46	Comprehensive outcomes after lung retransplantation: A single-center review. <i>Clinical Transplantation</i> , 2018, 32, e13281.	1.6	25
47	Precision Diagnostics in Transplantation: From Bench to Bedside. <i>American Journal of Transplantation</i> , 2013, 13, 562-568.	4.7	24
48	Impact of Deceased Donor Diabetes Mellitus on Kidney Transplant Outcomes: A Propensity Score-Matched Study. <i>Transplantation</i> , 2009, 88, 251-260.	1.0	23
49	A pilot study of reduced dose cyclosporine and corticosteroids to reduce new onset diabetes mellitus and acute rejection in kidney transplant recipients. <i>Transplantation Research</i> , 2013, 2, 1.	1.5	23
50	High-Resolution HLA Typing for Sensitized Patients: Advances in Medicine and Science Require Us to Challenge Existing Paradigms. <i>American Journal of Transplantation</i> , 2015, 15, 2780-2781.	4.7	23
51	In praise of ventricular assist devices—mechanical bridge to virtual crossmatch for the sensitized patient. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 728-730.	0.6	18
52	ATG induction is associated with an increase in anti-HLA antibodies after kidney transplantation. <i>Human Immunology</i> , 2004, 65, 1281-1287.	2.4	17
53	Development and Impact of De Novo Anti-HLA Antibodies in Pediatric Heart Transplant Recipients. <i>American Journal of Transplantation</i> , 2015, 15, 2215-2222.	4.7	17
54	De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?. <i>Clinical Transplantation</i> , 2018, 32, e13416.	1.6	17

#	ARTICLE	IF	CITATIONS
55	Generation of Antigen Microarrays to Screen for Autoantibodies in Heart Failure and Heart Transplantation. PLoS ONE, 2016, 11, e0151224.	2.5	16
56	Long-term outcomes of sensitized lung transplant recipients after peri-operative desensitization. American Journal of Transplantation, 2021, 21, 3444-3448.	4.7	16
57	Reciprocity to Increase Participation of Compatible Living Donor and Recipient Pairs in Kidney Paired Donation. American Journal of Transplantation, 2017, 17, 1723-1728.	4.7	15
58	Extracorporeal photopheresis in solid organ transplant-associated acute graft-versus-host disease. Transfusion, 2016, 56, 962-969.	1.6	12
59	Systemic immunosuppression in limbal stem cell transplantation: best practices and future challenges. Canadian Journal of Ophthalmology, 2018, 53, 314-323.	0.7	12
60	Transplantation tolerance in pediatric recipients: Lessons and challenges. Pediatric Transplantation, 2005, 9, 17-27.	1.0	10
61	Successful living donor kidney transplantation across HLA and ABO incompatibilities. Nephrology Dialysis Transplantation, 2006, 22, 602-604.	0.7	10
62	Basic Histocompatibility Testing Methods. , 2012, , 21-42.		10
63	Canadian Forum on Combined Organ Transplantation. Transplantation, 2016, 100, 1339-1348.	1.0	10
64	Peri-operative desensitization for highly sensitized heart transplant patients. Journal of Heart and Lung Transplantation, 2018, 37, 667-670.	0.6	10
65	Complementing donor-specific antibody testing. Nature Reviews Nephrology, 2013, 9, 713-714.	9.6	9
66	Donor-Specific Antibody Monitoring: Where Is the Beef?. Advances in Chronic Kidney Disease, 2016, 23, 317-325.	1.4	9
67	Sensitization assessment before kidney transplantation. Transplantation Reviews, 2017, 31, 18-28.	2.9	9
68	Measuring alloantibodies: a matter of quantity and quality. Current Opinion in Organ Transplantation, 2019, 24, 20-30.	1.6	9
69	Angiotensin II Type 1 Receptor Antibodies: Great Expectations?. American Journal of Transplantation, 2013, 13, 2515-2516.	4.7	8
70	C4d immunostaining is an independent predictor of cardiac allograft vasculopathy and death in heart transplant recipients. Transplant International, 2015, 28, 857-863.	1.6	8
71	An Integrated Clinical and Genetic Prediction Model for Tacrolimus Levels in Pediatric Solid Organ Transplant Recipients. Transplantation, 2021, Publish Ahead of Print, .	1.0	7
72	Transfusion-related acute lung injury (TRALI) in graft by blood donor antibodies against host leukocytes. Journal of Heart and Lung Transplantation, 2010, 29, 1067-1070.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Organ Donation and Transplantation. <i>Transplantation</i> , 2015, 99, 2231-2233.	1.0	5
74	The HLDA8 blind panel: Findings and conclusions. <i>Journal of Immunological Methods</i> , 2005, 305, 75-83.	1.4	4
75	De Novo DQ Donor-Specific Antibodies Are Associated With Chronic Lung Allograft Dysfunction. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, S98-S99.	0.6	3
76	Detecting antibodies with similar reactivity patterns in the HLDA8 blind panel of flow cytometry data. <i>Journal of Immunological Methods</i> , 2005, 305, 67-74.	1.4	2
77	Desensitization Outcomes: Quantifying and Questioning. <i>American Journal of Transplantation</i> , 2014, 14, 1475-1476.	4.7	2
78	Remote Mobile Outpatient Monitoring in Transplant (Reboot) 2.0: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2021, 10, e26816.	1.0	2
79	Donor Specific Antibodies in Heart Transplantation: Do Clinicians Need to do Something Always?. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, S107.	0.6	1
80	Intragraft donor-specific antibodies and lung transplantation. <i>European Respiratory Journal</i> , 2019, 54, 1901937.	6.7	1
81	Idiopathic Fulminant Graft Failure Rescued by Urgent ABO-Incompatible Liver Transplantation. <i>Progress in Transplantation</i> , 2021, 31, 190-192.	0.7	1
82	A sensitive approach. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 1042-1043.	0.6	0
83	Another piece of the antibody puzzle: Observations from the HALT study. <i>American Journal of Transplantation</i> , 2018, 18, 2111-2112.	4.7	0
84	Strategies to offer kidney transplant to highly sensitized patients. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 585-586.	0.7	0